Journal of Pharmaceutical Research International, ISSN: 2456-9119, ISSN: 2231-2919 (past),Vol.: 23, Issue.: 4
Chimeric Antigen Receptor T Cell (CAR – T) Therapy – A Novel Treatment in Cancer
Priyadarsini Baskaran1*, Venkatraman Karthikeayan2 and Anusha Natarajan1 1Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India. 2Gleneagles Global Hospital, Chennai, Tamil Nadu, India.
Priyadarsini Baskaran1*, Venkatraman Karthikeayan2 and Anusha Natarajan1
1Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India.
2Gleneagles Global Hospital, Chennai, Tamil Nadu, India.
(1) Dr. Rahul S. Khupse, Pharmaceutical Sciences, University of Findlay, USA.
(1) Lívia Garcia Bertolacci-Rocha, Universidade Federal de Goiás, Brasil.
(2) Thompson Akinbolaji, Yuma Regional Medical Center, USA.
(3) Poggi Alessandro, IRCCS AOU San Martino, Italy.
(4) Pratibha Kamble, University of Mumbai, India.
(5) Wagih Mommtaz Ghannam, Mansoura University, Egypt.
Complete Peer review History: http://www.sciencedomain.org/review-history/26188
Cancer is one of the most challenging diseases affecting mankind. It continues to defy all the treatment modalities and advancements and claims millions of lives every year. Chimeric Antigen Receptor –T (CAR-T) cell therapy is one of the breakthroughs in cancer treatment. Chimeric antigen receptor is a recombinant immunoreceptor that enables the T cells to recognise and kill tumour surface antigens in a non MHC (Major Histocompatibility Complex) restricted manner. There are four generations of CAR-T cells, of which the second generation CAR-T cells have maximum efficacy clinically. In 2017, two CAR-T cell therapies were approved by FDA for the treatment of ALL (Acute Lymphoblastic Leukaemia) and NHL (Non-Hodgkin's Lymphoma). More than 80% remission is achieved with these tumours which are resistant to all other treatment modalities. Now CAR-T cell therapies are being tested for non – haematological malignancies also. However, the adverse effects of CAR-T cell therapies are very severe like Cytokine Release syndrome (CRS) and on - target off - tumour toxicity. This review will attempt to cover the basic concept and the applications of CAR-T cells, their adverse effects, challenges faced and the future prospects of the CAR-T cells in treatment of cancer.
CAR-T therapy; chimeric antigen; anticancer agent.
DOI : 10.9734/JPRI/2018/43471Review History Comments